NO20013459D0 - Anvendelse av agiotensin II reseptorantagonister ved behandling av akutt myokardinfarkt - Google Patents

Anvendelse av agiotensin II reseptorantagonister ved behandling av akutt myokardinfarkt

Info

Publication number
NO20013459D0
NO20013459D0 NO20013459A NO20013459A NO20013459D0 NO 20013459 D0 NO20013459 D0 NO 20013459D0 NO 20013459 A NO20013459 A NO 20013459A NO 20013459 A NO20013459 A NO 20013459A NO 20013459 D0 NO20013459 D0 NO 20013459D0
Authority
NO
Norway
Prior art keywords
treatment
agiotensin
myocardial infarction
receptor antagonists
acute myocardial
Prior art date
Application number
NO20013459A
Other languages
English (en)
Other versions
NO20013459L (no
Inventor
Jessica M Mann
Pascale Oddou
Eric Michel Neuhart
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26153740&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20013459(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20013459D0 publication Critical patent/NO20013459D0/no
Publication of NO20013459L publication Critical patent/NO20013459L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
NO20013459A 1999-01-26 2001-07-12 Anvendelse av angiotensin II reseptorantagonister ved behandling av akutt myokardinfarkt NO20013459L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP99810061 1999-01-26
US46866499A 1999-12-21 1999-12-21
PCT/EP2000/000525 WO2000044378A1 (en) 1999-01-26 2000-01-24 Use of angiotensin ii receptor antagonists for treating acute myocardial infarction

Publications (2)

Publication Number Publication Date
NO20013459D0 true NO20013459D0 (no) 2001-07-12
NO20013459L NO20013459L (no) 2001-09-05

Family

ID=26153740

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20013459A NO20013459L (no) 1999-01-26 2001-07-12 Anvendelse av angiotensin II reseptorantagonister ved behandling av akutt myokardinfarkt

Country Status (25)

Country Link
EP (2) EP1146872B1 (no)
JP (1) JP2002535367A (no)
KR (1) KR100674053B1 (no)
CN (1) CN1337879A (no)
AT (1) ATE330599T1 (no)
AU (1) AU766453C (no)
BR (1) BR0007686A (no)
CA (1) CA2360691A1 (no)
CY (1) CY1105257T1 (no)
CZ (1) CZ20012682A3 (no)
DE (1) DE60028928T2 (no)
DK (1) DK1146872T3 (no)
ES (1) ES2265910T3 (no)
HK (1) HK1041808B (no)
HU (1) HUP0105199A3 (no)
ID (1) ID29818A (no)
IL (2) IL144216A0 (no)
NO (1) NO20013459L (no)
NZ (1) NZ513039A (no)
PL (1) PL197161B1 (no)
PT (1) PT1146872E (no)
RU (2) RU2298405C2 (no)
SI (1) SI1146872T1 (no)
SK (1) SK10522001A3 (no)
WO (1) WO2000044378A1 (no)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000038676A1 (en) * 1998-12-23 2000-07-06 Novartis Ag Use of at-1 receptor antagonist or at-2 receptor modulator for treating diseases associated with an increase of at-1 or at-2 receptors
EP1314425A4 (en) * 2000-08-30 2004-06-02 Sankyo Co MEDICINAL COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF HEART FAILURE
US7076287B2 (en) 2000-12-29 2006-07-11 Ge Medical Systems Information Technologies, Inc. System and method for detecting new left bundle branch block for accelerating treatment of acute myocardial infarction
EP1448190A2 (en) * 2001-10-18 2004-08-25 Novartis AG Salts formed of an at1-receptor antagonist and a cardiovascular agent
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
PL373202A1 (en) * 2002-05-17 2005-08-22 Novartis Ag Combination of angiotensin ii receptor blocker and beta-blocker for secondary prevention of myocardial infarction
SE0302331D0 (sv) * 2003-08-29 2003-08-29 Astrazeneca Ab New use II
WO2005030202A1 (en) * 2003-09-26 2005-04-07 Novartis Ag Use of angiotensin ii receptor antagonists for treating cerebrovascular disorders
WO2005053687A1 (en) * 2003-11-25 2005-06-16 Novartis Ag Combination of organic compounds
WO2009087116A1 (en) * 2008-01-11 2009-07-16 Novartis Ag Use of spp100 for the treatment of acute mi
CN104086623B (zh) * 2014-07-02 2017-05-24 牡丹江友搏药业有限责任公司 一种新的具有降压和细胞保护作用的化合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9027208D0 (en) * 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
EP0577025A3 (de) * 1992-07-01 1998-02-04 Hoechst Aktiengesellschaft Angiotensin-II-Rezeptorantagonisten zur Behandlung und Prophylaxe von koronaren Herzerkrankungen
FR2716882B1 (fr) * 1994-03-04 1996-04-05 Roussel Uclaf Utilisation de dérivés de l'imidazole au traitement d'affections impliquant les récepteurs AT1 et AT2 de l'Angiotensine, certains de ces produits, leur préparation, compositions pharmaceutiques.
DE4432860A1 (de) * 1994-09-15 1996-03-21 Merck Patent Gmbh Imidazopyridine
GB9613470D0 (en) * 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
US5795904A (en) * 1996-12-06 1998-08-18 Merck & Co., Inc. Enhanced functional recovery of the heart by losartan treatment after an ischemic attach

Also Published As

Publication number Publication date
AU2439700A (en) 2000-08-18
CN1337879A (zh) 2002-02-27
IL144216A (en) 2007-07-04
PT1146872E (pt) 2006-10-31
HK1041808B (zh) 2007-01-19
HK1041808A1 (en) 2002-07-26
NZ513039A (en) 2003-11-28
AU766453C (en) 2004-11-25
KR100674053B1 (ko) 2007-01-25
ID29818A (id) 2001-10-11
DE60028928D1 (de) 2006-08-03
ATE330599T1 (de) 2006-07-15
ES2265910T3 (es) 2007-03-01
CZ20012682A3 (cs) 2001-10-17
DK1146872T3 (da) 2006-10-16
NO20013459L (no) 2001-09-05
PL197161B1 (pl) 2008-03-31
KR20020002379A (ko) 2002-01-09
JP2002535367A (ja) 2002-10-22
CA2360691A1 (en) 2000-08-03
RU2006135205A (ru) 2008-04-10
RU2345790C2 (ru) 2009-02-10
EP1146872A1 (en) 2001-10-24
AU766453B2 (en) 2003-10-16
DE60028928T2 (de) 2007-01-04
BR0007686A (pt) 2001-11-06
SI1146872T1 (sl) 2006-12-31
EP1714651A1 (en) 2006-10-25
HUP0105199A2 (hu) 2002-04-29
RU2298405C2 (ru) 2007-05-10
HUP0105199A3 (en) 2004-11-29
WO2000044378A1 (en) 2000-08-03
IL144216A0 (en) 2002-05-23
CY1105257T1 (el) 2010-03-03
SK10522001A3 (sk) 2001-12-03
EP1146872B1 (en) 2006-06-21

Similar Documents

Publication Publication Date Title
CY1105257T1 (el) Χρηση των ανταγωνιστων των υποδοχεων της αγγειοτενσινης ii στην θepαπεια του οξεος εμφραγματος του μυοκαρδιου
WO2002099388A3 (en) Benzodiazepine bradykinin antagonists
MX9603259A (es) Tratamiento de glaucoma normotensivo con antagonistas de angiotensina ii.
HUP0104085A3 (en) Use of vasopressin antagonists for the preparation of pharmaceutical compositions treating pulmonary hypertension
HUP0202734A3 (en) Use of pegylated interfron alfa-ccr5 antagonist combination for hiv therapy
ATE295183T1 (de) Mittel zur linderung von juckreiz, enthaltend pgd2- antagonisten
WO2002072093A3 (en) Use of dual h3/m2 antagonists with a bipiperidinic structure in the treatment of cognition deficit disorders
EA200100089A1 (ru) Предотвращение рецидива мигрени
IL145645A0 (en) N-(2-phenyl-4-amino-butyl)-1-naphthamides as neurokinin-1 receptor antagonists
EA200601592A1 (ru) Фармацевтическая композиция, содержащая ингибитор pde4 или pde3/4 и антагонист гистаминового рецептора
CY1105302T1 (el) Μη-πεπτιδιο ανταγωνιστες υποδοχεα ccr1 για την θepαπεια προϊουσης νεφρικης ινωσης
CY1105321T1 (el) Μη πεπτιδικοι ανταγωνιστες υποδοχεα ccr1 σε συνδυασμο με κυκλοσπορινη α για τη θepαπεια της απορριψης καρδιακου μοσχευματος
BR0000486A (pt) Antagonistas do neuropeptìdeo y
DK1212119T3 (da) Anvendelse af cyamemazin ved behandling af brat seponering af benzodiazepiner
SE0302331D0 (sv) New use II
EA200401617A1 (ru) Комбинация nmda-антагониста и ингибиторов ацетилхолинэстеразы для лечения болезни альцгеймера
LT2003015A (en) Non-peptide ccr1 receptor antagonists in combination with cyclosporin a for the treatment of heart transplant rejection

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application